ArticleInternational microbiology : the official journal of the Spanish Society for Microbiology2025
Fungal mediated production of novel metabolites of meloxicam and their tankyrase-2 inhibition potentials: an in silico study.
Article in International microbiology : the official journal of the Spanish Society for Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current study focuses on the isolation of a thermophilic fungus capable of biotransforming meloxicam to produce novel metabolites with potential tankyrase inhibitory properties. The isolated strain is identified as Rhizomucor pusillus, confirmed through both morphological and molecular methodologies. The biotransformation process was monitored using high-performance liquid chromatography (HPLC) in conjunction with a two-stage fermentation approach. Previous research, along with LC-MS/MS analyses, has successfully characterized the metabolites generated, providing structural validation. This fungus enabled the conversion of meloxicam into four metabolites: 5-hydroxy methyl meloxicam (M1), 5-carboxy meloxicam (M2), and two previously unreported metabolites (M3 and M4), under controlled conditions of pH 6.0 and a temperature of 40 °C over a 3-day shaking culture period. The fungal strain R. pusillus has demonstrated the ability to generate notable metabolites of meloxicam, particularly M1 and M2, as evidenced by research conducted on mammals. Moreover, in silico analyses have revealed the presence of two novel metabolites that may inhibit tankyrase-2. This finding indicates that R. pusillus possesses an enzymatic system comparable to that found in mammals, facilitating the environmentally sustainable and economically viable production of metabolites. Additionally, this strain is capable of synthesizing substantial amounts of metabolites that could potentially exhibit pharmacological effects.
Indexed as
Identifiers
40019717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.